Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.

Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, Musella F, Gargiulo P, Marciano C, Perrone-Filardi P.

J Am Coll Cardiol. 2012 Sep 25;60(13):1192-201. doi: 10.1016/j.jacc.2012.01.083.

2.

Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.

Frantz RP, McDevitt S, Walker S.

J Heart Lung Transplant. 2012 Aug;31(8):811-6. doi: 10.1016/j.healun.2012.04.005.

PMID:
22759797
3.

Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.

Zhu B, Wang L, Sun L, Cao R.

J Cardiovasc Pharmacol. 2012 Oct;60(4):342-6. doi: 10.1097/FJC.0b013e318262a793. Review.

PMID:
22691882
4.

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.

Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E.

Respirology. 2008 Sep;13(5):674-82. doi: 10.1111/j.1440-1843.2008.01326.x.

PMID:
18713089
5.

Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.

Degano B, Sitbon O, Savale L, Garcia G, O'Callaghan DS, Jaïs X, Humbert M, Simonneau G.

Chest. 2010 Jun;137(6):1297-303. doi: 10.1378/chest.09-2060. Epub 2010 Jan 29.

PMID:
20118205
6.

Combination therapy in pulmonary arterial hypertension: a meta-analysis.

Bai Y, Sun L, Hu S, Wei Y.

Cardiology. 2011;120(3):157-65. doi: 10.1159/000334431. Epub 2011 Dec 29. Review.

PMID:
22212696
7.

Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.

Savarese G, Musella F, D'Amore C, Losco T, Marciano C, Gargiulo P, Rengo G, Dellegrottaglie S, Bossone E, Leosco D, Perrone-Filardi P.

Eur Respir J. 2013 Aug;42(2):414-24. doi: 10.1183/09031936.00123712. Epub 2012 Oct 25.

8.

Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.

He CJ, Chen SJ, Wang J, Zhu CY, Yin YH.

Pulm Pharmacol Ther. 2015 Jun;32:24-8. doi: 10.1016/j.pupt.2015.03.002. Epub 2015 Apr 2.

PMID:
25843006
9.

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.

Gaine S, Simonneau G.

Eur Respir Rev. 2013 Dec;22(130):487-94. doi: 10.1183/09059180.00006213. Review.

10.

Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.

Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.

J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011. Epub 2011 May 4.

PMID:
21531577
11.

Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

Ryerson CJ, Nayar S, Swiston JR, Sin DD.

Respir Res. 2010 Jan 29;11:12. doi: 10.1186/1465-9921-11-12. Review.

12.

Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension.

Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G.

Eur Respir J. 2006 Jan;27(1):114-20.

13.

Is pulmonary vascular resistance index predictive of exercise tolerance in adult patients with idiopathic pulmonary arterial hypertension.

Lawrence JP, Hung J, Wang SJ.

Contemp Clin Trials. 2012 Nov;33(6):1217-24. doi: 10.1016/j.cct.2012.07.008. Epub 2012 Jul 20.

PMID:
22820321
14.

New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension.

Preston IR, Suissa S, Humbert M.

Eur Respir Rev. 2013 Dec;22(130):495-502. doi: 10.1183/09059180.00006413. Review.

15.

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.

Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group.

J Am Coll Cardiol. 2002 May 1;39(9):1496-502.

16.

Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.

Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM.

Chest. 2013 Feb 1;143(2):315-23.

17.

Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.

Huang J, Mehta S, Mura M.

Respiration. 2015;89(5):365-73. doi: 10.1159/000370124. Epub 2015 Mar 13.

PMID:
25791910
18.

Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.

Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1111-7. doi: 10.1164/rccm.201507-1456OC.

PMID:
26291092
19.
20.

Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension.

Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):400-8. doi: 10.1164/rccm.201105-0848OC. Epub 2011 Nov 22.

PMID:
22108205
Items per page

Supplemental Content

Write to the Help Desk